CAN508

CAN508 is a potent, ATP-competitive CDK9/cyclin T1 inhibitor with an IC50 of 0.35 μM. CAN508 exhibits a 38-fold selectivity for CDK9/cyclin T over other CDK/cyclin complexes. Antitumor activity[1][2].

Product Specifications

CAS Number

[140651-18-9]

UNSPSC

12352005

Hazard Statement

H302-H318-H410

Target

CDK

Type

Reference compound

Related Pathways

Cell Cycle/DNA Damage

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/can508.html

Purity

99.59

Solubility

DMSO : 250 mg/mL (ultrasonic)

Smiles

OC1=CC=C(/N=N/C2=C(N)NN=C2N)C=C1

Molecular Formula

C9H10N6O

Molecular Weight

218.22

Precautions

P264-P270-P273-P280-P305+P351+P338-P330-P391-P501

References & Citations

[1]Krystof V, et al. 4-arylazo-3,5-diamino-1H-pyrazole CDK inhibitors: SAR study, crystal structure in complex with CDK2, selectivity, and cellular effects. J Med Chem. 2006;49 (22) :6500-6509.|[2]Tong Z, et al. Antitumor effects of cyclin dependent kinase 9 inhibition in esophageal adenocarcinoma. Oncotarget. 2017;8 (17) :28696-28710.